|
Antimicrobial
|
Disk Diffusion
| | | | | | | |
|---|
| |
Disc content
|
Zone diameters* (mm)
|
Equivalent MICs breakpoints * (mg/l)
|
Results of disk diffusion n (%)
|
| | |
S
|
R
|
S
|
R
|
S
|
I
|
R
|
|
Amikacin
|
30 μg
|
≥17
|
<15
|
≤8
|
>16
|
25 (47,2)
|
1 (1,9)
|
27 (50,9)
|
|
Tobramycin
|
10 μg
|
≥16
|
<16
|
≤4
|
>4
|
36 (67,9)
|
0
|
17 (32,1)
|
|
Gentamycin
|
15 μg
|
≥16
|
<16
|
≤4
|
>4
|
1 (1,9)
|
0
|
52 (98,1)
|
|
Ampicillin/Sulbactam‡
|
10 μg/10 μg
|
≥15
|
≤11
|
≤8/4
|
≥32/16
|
42 (79.2)
|
0
|
11 (20.8)
|
|
Ticarcillin/clavulanic acid
|
75/10 μg
|
≥22
|
<18
|
≤16/2
|
>64/2
|
1 (1,9)
|
0
|
52 (98,1)
|
|
Piperacilin-Tazobactam
|
75/10 μg
|
≥19
|
<14
|
≤16/4
|
>64/4
|
0
|
1 (1,9)
|
52 (98,1)
|
|
Ceftazidime
|
30 μg
|
≥21
|
<19
|
≤4
|
>8
|
3 (5,7)
|
0
|
50 (94,3)
|
|
Ciprofloxacin
|
5 μg
|
≥22
|
<19
|
≤1
|
>2
|
1 (1,9)
|
0
|
52 (98,1)
|
|
Sulfamethoxazole/trimethoprim
|
23.75/1.25 μg
|
≥16
|
<13
|
≤38/2
|
>76/4
|
0
|
0
|
53 (100)
|
|
Imipenem
|
10 μg
|
≥24
|
<17
|
≤2
|
>8
|
0
|
4 (7.5)
|
49 (92.5)
|
|
Colistin
|
50 μg
|
≥15
|
<15
|
≤2
|
>2
|
53 (100)
|
0
|
0
|
| |
MICs
| | |
S
|
R
|
MIC50 (mg/l) MIC 90 (mg/l)
|
|
Imipenem
| | | |
≤2
|
>8
|
32
| |
32
|
|
Meropenem
| | | |
≤2
|
>8
|
≥32
| |
≥32
|
- *: According to the Antibiogram Committee of the French Microbiology Society except for Ampicillin/sulbactam
- ‡: According to the Clinical and Laboratory Standards Institute
- S: susceptible; I: intermediate; R: resistant.
